Ceftriaxone in Patients with ALS
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To
determine the pharmacokinetics, safety and tolerability of long term
cefriaxone treatment as well as to ascertain whether chronic treatment
with ceftriaxone prolongs survival in patients with ALS.
Who is Eligible to Participate?
Patients
18 years or older with familial or sporadic ALS.
Patients will also have to meet all exclusionary criteria which will
be explained in greater detail by the study coordinator.
What is involved in this Study?
Patients 18 years or older with familial or sporadic ALS. Patients
may be on riluzole, but have to be on a stable dose for at least 30 days
prior to screening. Patients will also have to meet all exclusionary criteria
which will be explained in greater detail by the study coordinator.
How
long is the Study?
The
study will be approximately 52 weeks long.
For More Information Contact: Nicole C. Hank, MHSM, study coordinator,
at 602-258-3354 ext 137 or nhank@pnal.net or call the Main line at 602-258-3354
|
